Scarica l'app Stockscreener
3.515
2.63%
-0.095
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$3.61
Aprire:
$3.61
Volume 24 ore:
715.12K
Relative Volume:
0.12
Capitalizzazione di mercato:
$637.54M
Reddito:
$4.03M
Utile/perdita netta:
$-198.37M
Rapporto P/E:
-2.8008
EPS:
-1.255
Flusso di cassa netto:
$-158.74M
1 W Prestazione:
+0.43%
1M Prestazione:
+12.30%
6M Prestazione:
-3.96%
1 anno Prestazione:
-37.79%
Intervallo 1D:
$3.45
$3.61
Intervallo di 1 settimana:
$3.3001
$4.14
Portata 52W:
$2.67
$6.65
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.515 | 637.54M | 4.03M | -198.37M | -158.74M | -1.255 |
VRTX
Vertex Pharmaceuticals Inc
|
497.41 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
210.80 | 84.16B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
756.09 | 77.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.39 | 50.90B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.48 | 41.26B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-25 | Ripresa | Chardan Capital Markets | Buy |
| 2026-08-19 | Iniziato | BMO Capital Markets | Outperform |
| 2026-06-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2026-03-12 | Iniziato | Oppenheimer | Outperform |
| 2025-05-27 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins - Timothy Sykes
PRME Stock Climbs As FDA Greenlights Gene-Editing Trials - StocksToTrade
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Australia
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease - GlobeNewswire Inc.
Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1%Still a Buy? - MarketBeat
PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade
Prime Medicine Stock Slips As Traders Digest Weak Margins - StocksToTrade
Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha
Prime Medicine stock surges on FDA IND clearance - Yahoo Finance
FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan
Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions - Simply Wall Street
Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine (Nasdaq:PRME)Stock Analysis - Simply Wall Street
Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - kalkinemedia.com
Prime Medicine (NASDAQ:PRME) Shares Up 11.8%Should You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3%Here's What Happened - MarketBeat
A gene-editing company sets three September conference appearances - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7%What's Next? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 6.3%Here's What Happened - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Company Profile & Introduction - Moomoo
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget
PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the DayConsensus Beat Rate - vinanet.vn
BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada
Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView
PRME Q2 2026 Earnings: Narrower-than-Expected Loss Marks Progress as Stock SlipsProfit Announcement - vinanet.vn
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat
Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Prime Medicine (NASDAQ:PRME) Trading Up 7.3%Still a Buy? - MarketBeat
Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Weekly Recap: Q2 loss/runway into 2027 and PM647 arbitration win, IND Q3 - TradingView
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME - MarketBeat
PRME Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.57% Stock AdvanceGuidance Downgrade Alert - vinanet.vn
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):